Premium
The role of Anti‐ VEGF s in the management of DME in vitrectomized eyes
Author(s) -
Kourentis C.
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2015.0246
Subject(s) - medicine , ophthalmology
Summary The role of Anti‐ VEGF s in the management of diabetic macula edema ( DME ) is well established in large, randomized, controlled studies in eyes with naïve vitreous. The effect of Anti‐ VEGF s may be altered in vitrectomized eyes and the question arises whether there is a difference in the efficacy of Anti‐ VEGF s after vitrectomy. The replacement of the vitreous gel facilitates oxygen transport to the retina, as well as clearance of VEGF , thus VEGF and Anti‐ VEGF pharmacokinetics can be altered. Pharmacokinetic data are largely based on experimental animal models but there is also a clinical impression that vitrectomized eyes have augmented pharmacokinetics with a faster clearance of Anti‐ VEGF s and therefore their treatment could be less effective and requiring shorter treatment intervals, compared to non‐vitrectomized eyes. According to a study presented January 2015, vitrectomized eyes fared as well as non.vitrectomized eyes after treatment with ranibizumab for diabetic macular edema.